Exscientia builds AWS AI-powered platform to advance drug discovery

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Exscientia plc announced it will be expanding its work with Amazon Web Services to use the cloud provider’s artificial intelligence and machine learning services to power its platform for end-to-end drug discovery and automation.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The National Institute for Health Care Management Foundation is now accepting letters of inquiry for the 2025-2026 funding cycle of NIHCM Foundation’s Research Grant program. We will be awarding a total of $500,000 in grants to support innovative, independent, investigator-initiated research that has the potential to inform managed care organizations, policymakers, and related stakeholders to improve the affordability and quality of U.S. health care. 
Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login